NCT06251895 is a clinical trial of DKA protocol in Diabetic Ketoacidosis, sponsored by Jahra Hospital.

Who is sponsoring NCT06251895?

NCT06251895 is sponsored by Jahra Hospital.

What drugs are being tested in NCT06251895?

Interventions in NCT06251895: DKA protocol.

What condition does NCT06251895 study?

NCT06251895 studies Diabetic Ketoacidosis.

Is NCT06251895 still recruiting?

NCT06251895 is currently completed. Last updated 9 February 2024.

Last reviewed 2024-02-09 · How we verify

NCT06251895

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association of Systemic Immune-inflammation Index and Severity of Diabetic Ketoacidosis in Type 1 Diabetes Mellitus

Completed Last updated 9 February 2024

What this trial tests

trial testing DKA protocol in Diabetic Ketoacidosis in 241 participants. Completed in 11 November 2023.

Timeline

1 August 2021

Primary endpoint
31 December 2022

11 November 2023

Quick facts

Lead sponsor	Jahra Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	241
Start date	1 August 2021
Primary completion	31 December 2022
Estimated completion	11 November 2023
Sites	1 location across Kuwait

Drugs / interventions tested

DKA protocol

Conditions studied

Diabetic Ketoacidosis — all drugs for Diabetic Ketoacidosis →

Sponsor

Jahra Hospital

Who can join

12 and older, any sex, with Diabetic Ketoacidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diabetic ketoacidosis (DKA) is the most serious metabolic complication of type 1 diabetes mellitus (T1DM). Insulin deficiency and inflammation play a role in the pathogenesis of DKA. The investigators aim to assess the systemic immune-inflammation index (SII) as a marker of severity among T1DM patients with DKA and without infection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Association of the systemic immune-inflammation index (SII) and severity of diabetic ketoacidosis in patients with type 1 diabetes mellitus: a retrospective cohort study.
Aon M, Aoun AH, Alshami A, Alharbi A, et al · · 2024 · cited 6× · PMID 38989212 · DOI 10.1097/ms9.0000000000002185

Verify or expand the search:

Other recruiting trials for Diabetic Ketoacidosis

Currently open trials in the same condition.

NCT07167693 — Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes · Phase 1, PHASE2 · recruiting
NCT07127406 — Postoperative Euglycemic Ketoacidosis Frequency in Sodium-Glucose Cotransporter-2 Inhibitor Users · active not recruiting
NCT06955416 — REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis · Phase 2, PHASE3 · recruiting
NCT07193069 — Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06251895 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jahra Hospital
Last refreshed: 9 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06251895.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing